Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

Mark R. Albertini,Zachary S. Morris,Jacquelyn A. Hank,Erik A. Ranheim,Cindy L. Zuleger,Kimberly A. McDowell,Renae M Quale,Molly Monson,Erin Clements,Tamara Koehn,Heather B. Neuman,Sharon M. Weber,Jennifer M. Racz,Mary Beth Henry,Emily Reinstad,KyungMann Kim,Stephen D. Gillies,Paul M. Sondel

Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

2021

Mark R. Albertini
Zachary S. Morris
Jacquelyn A. Hank
Erik A. Ranheim
Cindy L. Zuleger
Kimberly A. McDowell
Renae M Quale
Molly Monson
Erin Clements
Tamara Koehn
Heather B. Neuman
Sharon M. Weber
Jennifer M. Racz
Mary Beth Henry
Emily Reinstad
KyungMann Kim
Stephen D. Gillies
Paul M. Sondel

TPS9591Background: We are studying an intratumoral (IT) in situ vaccine strategy using the GD2-reactive hu14.18-IL2 immunocytokine (hu-IC) to convert the injected tumor into a site of enhanced tumo...

Keywords:

Medicine
Internal medicine
Nivolumab
Ipilimumab
Oncology
Hu14.18-IL2
advanced melanoma
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations